Jounce Therapeutics picks up $56 mln Series B
Cambridge, Massachusetts-based Jounce Therapeutics, which is focused on discovering and developing cancer immunotherapies, has closed $56 million in Series B funding. The investors included Wellington Management Company, Redmile Group, Nextech Invest, Pharmstandard International, S.A., Cormorant Asset Management, Omega Funds, Casdin Capital and Foresite Capital Management.
23 April 2015•3 mins read
